专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120135952A1 BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME 审中-公开
标题翻译： N，N-二甲基咪唑基偶氮二异丁酸的丁酸盐，其制备方法和药物组合物以及含有它们的组合
公开(公告)号：US20120135952A1
公开(公告)日：2012-05-31
申请号：US13384218
申请日：2010-07-16
申请人： Sung Wuk Kim , Sung Soo Jun , Changhee Min , Min Seok Kang , Yong Eun Kim , Ja Seong Koo
发明人： Sung Wuk Kim , Sung Soo Jun , Changhee Min , Min Seok Kang , Yong Eun Kim , Ja Seong Koo
IPC分类号： A61K31/155 , C07C277/00 , A61P35/00 , A61K31/7068 , A61P3/06 , A61P19/08 , A61P9/00 , A61P3/10 , C07C279/26 , A61P9/12
CPC分类号： A61K31/155 , C07C53/124 , C07C279/26
摘要： The present invention provides metformin butyric acid salt, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin butyric acid salt according to the present invention has an excellent pharmacological effect as compared with metformin hydrochloride and is capable of achieving a therapeutic purpose by administering an amount less than metformin hydrochloride. Furthermore, the metformin butyric acid salt has excellent physicochemical properties, such as solubility, stability, hygroscopicity and adsorption preventing property, in processibility of formulations and thereby is capable of being usefully utilized as a pharmaceutically acceptable salt of the metformin.
摘要翻译：本发明提供了二甲双胍丁酸盐，其制备方法，药物组合物和含有它们的组合物。与二甲双胍盐酸盐相比，本发明的二甲双胍丁酸盐具有优异的药理作用，能够通过施用少于二甲双胍盐酸盐的量来达到治疗目的。此外，二甲双胍丁酸盐在制剂的加工性方面具有优异的物理化学性质，例如溶解性，稳定性，吸湿性和吸附防止性，因此能够有效地用作二甲双胍的药学上可接受的盐。

2. 发明授权

US09416098B2 Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient 有权
标题翻译：双胍衍生物，其制备方法和含有双胍衍生物作为活性成分的药物组合物
公开(公告)号：US09416098B2
公开(公告)日：2016-08-16
申请号：US13520902
申请日：2011-01-06
申请人： Sung Wuk Kim , Sung Soo Jun , Chang Hee Min , Young Woong Kim , Min Seok Kang , Byung Kyu Oh , Se Hwan Park , Yong Eun Kim , Duck Kim , Ji Sun Lee , Ju Hoon Oh
发明人： Sung Wuk Kim , Sung Soo Jun , Chang Hee Min , Young Woong Kim , Min Seok Kang , Byung Kyu Oh , Se Hwan Park , Yong Eun Kim , Duck Kim , Ji Sun Lee , Ju Hoon Oh
IPC分类号： C07C277/02 , C07C279/02 , A61K31/155 , C07C279/26 , C07C277/04 , C07C279/04 , C07C279/06 , C07C279/08 , C07C279/18 , C07D213/38 , C07D307/52 , C07D317/58 , C07D333/20
CPC分类号： A61K31/155 , A61K31/341 , A61K31/4406 , A61K31/472 , C07C277/04 , C07C279/04 , C07C279/06 , C07C279/08 , C07C279/16 , C07C279/18 , C07C279/26 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2603/74 , C07D213/38 , C07D307/52 , C07D317/58 , C07D333/20
摘要： A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
摘要翻译：提供了由式1表示的具有N1-N5取代基的双胍衍生化合物或其药学上可接受的盐，其制备方法和含有它们作为活性成分的药物组合物。与常规药物相比，双胍衍生物可能对AMPKα的活化和低剂量的癌细胞增殖具有优异的作用，因此可用于治疗糖尿病，肥胖症，高脂血症，高胆固醇血症，脂肪肝，冠状动脉疾病，骨质疏松症，多囊卵巢综合征，代谢综合征，癌症等

3. 发明申请

US20120283299A1 Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient 有权
标题翻译：双胍衍生物及其制备方法及含有双胍衍生物作为活性成分的药物组合物
公开(公告)号：US20120283299A1
公开(公告)日：2012-11-08
申请号：US13520902
申请日：2011-01-06
申请人： Sung Wuk Kim , Sung Soo Jun , Chang Hee Min , Young Woong Kim , Min Seok Kang , Byung Kyu Oh , Se Hwan Park , Yong Eun Kim , Duck Kim , Ji Sun Lee , Ju Hoon Oh
发明人： Sung Wuk Kim , Sung Soo Jun , Chang Hee Min , Young Woong Kim , Min Seok Kang , Byung Kyu Oh , Se Hwan Park , Yong Eun Kim , Duck Kim , Ji Sun Lee , Ju Hoon Oh
IPC分类号： A61K31/155 , C07C277/08 , A61P3/10 , A61P3/04 , A61P3/06 , A61P1/16 , A61P19/10 , A61P35/00 , A61P29/00 , C07C279/18 , C07D213/58 , A61K31/4406 , C07C279/16 , C07C279/14 , A61K31/22 , C07D307/54 , A61K31/341 , C07C279/04
CPC分类号： A61K31/155 , A61K31/341 , A61K31/4406 , A61K31/472 , C07C277/04 , C07C279/04 , C07C279/06 , C07C279/08 , C07C279/16 , C07C279/18 , C07C279/26 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2603/74 , C07D213/38 , C07D307/52 , C07D317/58 , C07D333/20
摘要： A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
摘要翻译：提供了由式1表示的具有N1-N5取代基的双胍衍生化合物或其药学上可接受的盐，其制备方法和含有它们作为活性成分的药物组合物。与常规药物相比，双胍衍生物可能对AMPKα的活化和低剂量的癌细胞增殖具有优异的作用，因此可用于治疗糖尿病，肥胖症，高脂血症，高胆固醇血症，脂肪肝，冠状动脉疾病，骨质疏松症，多囊卵巢综合征，代谢综合征，癌症等

4. 发明申请

US20100143470A1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDES AND ANGIOTENSIN-II-RECEPTOR BLOCKERS 审中-公开
标题翻译：含有THIAZIDES和ANGIOTENSIN-II-受体阻断剂的受控释放的药物组合物
公开(公告)号：US20100143470A1
公开(公告)日：2010-06-10
申请号：US12447159
申请日：2007-10-30
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jin Wook Kim , Jae Woon Son
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jin Wook Kim , Jae Woon Son
IPC分类号： A61K31/5415 , A61K47/30 , A61K47/38 , A61K47/32 , A61K9/28 , A61P9/00 , A61P13/12
CPC分类号： A61K31/00 , A61K9/2086 , A61K9/209 , A61K31/549 , A61K45/06 , A61K2300/00
摘要： Disclosed herein is a pharmaceutical composition, containing a thiazide compound and an angiotensin-II-receptor blocker, and a technology for formulating the same. More particularly, disclosed is a pharmaceutical combination formulation of thiazide compound and angiotensin-II-receptor blocker, which maximizes the pharmacological and clinical antihypertensive effects and complication preventive effects of the drugs and reduces the side effects of the drugs, compared to when single-component formulations of the drugs are administered simultaneously.
摘要翻译：本文公开了含有噻嗪类化合物和血管紧张素-II-受体阻断剂的药物组合物及其制备方法。更具体地，公开了噻嗪类化合物和血管紧张素-II-受体阻断剂的药物组合制剂，其最大化药物的药理学和临床抗高血压作用和并发症预防作用，并降低药物的副作用，与单组分药物的配方同时给药。

5. 发明申请

US20110111022A1 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：US20110111022A1
公开(公告)日：2011-05-12
申请号：US12937313
申请日：2009-04-08
申请人： Sung Wuk Kim , Sung Soo Jun , Ja Seong Koo , Jin Wook Kim , Jae Woon Son , Young Gwan Jo
发明人： Sung Wuk Kim , Sung Soo Jun , Ja Seong Koo , Jin Wook Kim , Jae Woon Son , Young Gwan Jo
IPC分类号： A61K9/52 , A61K31/41 , A61K31/4184 , A61K31/4178 , A61K9/00 , A61K9/22 , A61P9/10 , A61P9/00 , A61P9/12 , A61P3/00
CPC分类号： A61K31/41 , A61K9/0004 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K9/5084 , A61K31/165 , A61K31/4178 , A61K31/4196 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an angiotensin-II-receptor blocker as a pharmacologically active ingredient. One of the compartments is an immediate-release compartment and the other one is an extended-release compartment. Since the disclosed formulation delivers the rennin inhibitor and angiotensin-II-receptor blocker at a specific delivery rate at a different time. It has an advantage in reducing the concern about side effects, improving drug effects, and simplifying the instructions for use of the drug. In addition, the formulation can pharmacologically, clinically, scientifically, and economically achieve more useful effects than the complex prescription case of taking the ingredients separately or each at once, in preventing and treating metabolic syndrome, cardiovascular disease and renal disease.
摘要翻译：本发明提供了包含含有作为药理活性成分的肾素抑制剂的隔室的药物制剂和具有作为药理活性成分的血管紧张素-II受体阻断剂的隔室。其中一个隔间是立即释放隔间，另一个是延长隔间。由于所公开的制剂在不同时间以特定的递送速率递送肾素抑制剂和血管紧张素-II-受体阻断剂。它有利于减少对副作用的关注，改善药物作用，并简化药物使用说明书。另外，与预防和治疗代谢综合征，心血管疾病和肾脏疾病有关的成分单独或每次立即使用的复杂处方情况下，该制剂在药理学，临床上，科学上和经济上都能获得更多的有用效果。

6. 发明申请

US20120015032A1 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME 审中-公开
标题翻译：包含HMG-COA还原酶和阿司匹林的抑制剂的组合制剂及其制备方法
公开(公告)号：US20120015032A1
公开(公告)日：2012-01-19
申请号：US12672630
申请日：2008-08-08
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Sang Ouk Sun
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Sang Ouk Sun
IPC分类号： A61K9/28 , A61P9/00 , A61P9/10 , A61K31/60
CPC分类号： A61K31/35 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.
摘要翻译：本发明涉及一种用于预防和治疗心血管疾病的时间疗法组合药物制剂，其基于以特定时间间隔施用多种药物的原则（即时间疗法）。具体地，组合的药物制剂包含HMG-CoA还原酶抑制剂，例如辛伐他汀和阿司匹林。因为组合的药物制剂是基于以特定时间间隔给药药物的原理而开发的，即所谓的时间疗法，与单独给药和单次制剂同时给药相比，它显示了预防或治疗心血管疾病的优异效果。此外，它是一种每日一次的剂型，其增加患者的药物依从性。特别是，尽管组合药物制剂中阿司匹林的含量降低，但组合药物制剂中阿司匹林的血小板聚集抑制作用等于现有技术中所用阿司匹林的量，而组合药物中阿司匹林制剂显示抗高血压作用。另外，按时间顺序组合的药物制剂允许两种彼此相互作用的药物长时间储存，并且组合的药物制剂确保了两种药物的人体安全性和功效。

7. 发明授权

US08076377B2 N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same 有权
标题翻译： N，N-二甲基亚氨基二酰亚胺二酰胺二羧酸酯，其制备方法和包含其的药物组合物
公开(公告)号：US08076377B2
公开(公告)日：2011-12-13
申请号：US12733711
申请日：2008-09-19
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim , Byoung Ha Kim , Duck Kim
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim , Byoung Ha Kim , Duck Kim
IPC分类号： A01N37/52 , A01N37/10 , A61K31/155 , A61K31/235
CPC分类号： C07C279/26 , C07C55/08 , C07C55/12 , C07C55/14 , C07C59/245
摘要： Disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.
摘要翻译：本文公开了N，N-二甲基亚氨基二亚甲基二酰胺的新型二羧酸盐及其制备方法和包含其的药物组合物。更具体地，本文公开了N，N-二甲基亚氨基二甲酰亚胺二酰胺的新型二羧酸盐，通过使N，N-二甲基亚氨基二碳二亚胺二酰胺与特定二羧酸反应制备的结晶酸加成盐，其具有改善的物理和化学性质，包括溶解度稳定性，非吸湿性和抗粘连性，低毒性，因此在预防和治疗不仅糖尿病及其所谓的代谢综合征患者的并发症方面非常有效，其中糖尿病，肥胖，高脂血症，脂肪肝，冠状动脉疾病，骨质疏松症，多囊卵巢综合征等组合，还包括p53基因缺陷型癌症，肌肉酸痛，肌肉细胞毒性和横纹肌溶解症，以及其制备方法和包含其的药物组合物。

8. 发明授权

US08058312B2 N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same 有权
标题翻译： N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其制备方法和包含其的药物组合物
公开(公告)号：US08058312B2
公开(公告)日：2011-11-15
申请号：US12524695
申请日：2008-01-29
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim
IPC分类号： A01N37/52 , A61K31/155 , C07C277/00 , C07C279/00
CPC分类号： A61K31/155 , C07C279/26
摘要： The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.
摘要翻译：本发明涉及N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其制备方法和包含其的药物组合物，更具体地涉及作为结晶酸加成盐的N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其是由使N，N-二甲基亚氨基二亚甲基二酰胺与乙酸反应，作为治疗代谢综合征的糖尿病，糖尿病，肥胖症，高脂血症，脂肪肝，冠心病，骨质疏松症，多囊卵巢综合症，癌症，贫血基因P53等复杂发生; 治疗糖尿病并预防其并发症; 并且由于酸加成盐在溶解性，稳定性，非吸湿性，抗附着性等等的物理化学性质和低毒性方面都是优异的，因此治疗癌症并防止肌肉痛，肌肉细胞毒性和横纹肌溶解等。的制备方法和包含其的药物组合物。

9. 发明申请

US20110052683A1 PHARMACEUTICAL PREPARATION FOR TREATING CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：US20110052683A1
公开(公告)日：2011-03-03
申请号：US12918882
申请日：2009-02-21
申请人： Sung Wuk Kim , Sung Soo Jun , Ja Seong Koo , Young Joo Lee , Seok Young Jang , Young Gwan Jo
发明人： Sung Wuk Kim , Sung Soo Jun , Ja Seong Koo , Young Joo Lee , Seok Young Jang , Young Gwan Jo
IPC分类号： A61K9/52 , A61K31/554 , A61K31/366 , A61K31/22 , A61K9/22 , A61K9/24 , A61K9/00 , A61P9/00 , A61K31/505 , A61K31/47 , A61K31/405
CPC分类号： A61K9/2866 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/2095 , A61K9/4808 , A61K9/5026 , A61K9/5042 , A61K9/5078 , A61K9/5084 , A61K31/00 , A61K31/22 , A61K31/366 , A61K31/405 , A61K31/47 , A61K31/505 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical preparation comprising a prior-release compartment containing a hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor as a pharmacologically active ingredient, and a delayed-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. The preparation of the present invention provides synergistic effects through combined administration of the non-dihydropyridine calcium channel blocker and the HMG-CoA reductase inhibitor, and induces the time-dependent absorption, metabolism and action mechanism of individual drugs through the controlled release thereof to avoid competitive antagonism between drugs, thus maximizing the effects of each pharmacologically active ingredient while minimizing side effects, for example, the risk of myopathy, and substantially increasing the compliance of patients by taking one tablet once a day.
摘要翻译：本发明提供了包含含有羟甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂作为药理活性成分的释放前隔室和含有非二氢吡啶类钙通道阻滞剂作为药理活性成分的缓释室的药物制剂。本发明的制备通过联合施用非二氢吡啶类钙通道阻滞剂和HMG-CoA还原酶抑制剂提供了协同效应，并通过其控制释放诱导各药物的时间依赖性吸收，代谢和作用机制，以避免药物之间的竞争性对抗，从而最大限度地发挥每种药理活性成分的作用，同时尽量减少副作用，例如肌病的风险，并通过每天服用一片药物来显着提高患者的依从性。

10. 发明申请

US20100087544A1 N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 有权
标题翻译： N，N-二甲基咪唑二羧酸二乙酸酯，其制备方法和包含其的药物组合物
公开(公告)号：US20100087544A1
公开(公告)日：2010-04-08
申请号：US12524695
申请日：2008-01-29
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim
IPC分类号： A61K31/155 , C07C279/00 , A61P3/04 , A61P3/10 , A61P9/00 , A61P35/00 , A61P19/10
CPC分类号： A61K31/155 , C07C279/26
摘要： The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.
摘要翻译：本发明涉及N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其制备方法和包含其的药物组合物，更具体地涉及作为结晶酸加成盐的N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其是由使N，N-二甲基亚氨基二亚甲基二酰胺与乙酸反应，作为治疗代谢综合征的糖尿病，糖尿病，肥胖症，高脂血症，脂肪肝，冠心病，骨质疏松症，多囊卵巢综合征，癌症，贫血基因P53等复杂发生; 治疗糖尿病并预防其并发症; 并且由于酸加成盐在溶解性，稳定性，非吸湿性，抗附着性等等的物理化学性质和低毒性方面都是优异的，因此治疗癌症并防止肌肉痛，肌肉细胞毒性和横纹肌溶解等。的制备方法和包含其的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式